Multi-state cannabis operator Curaleaf Holdings (CSE:CURA) dropped in value following its debut in the Canadian public market on Monday (October 29).

Curaleaf, formerly Lead Ventures, completed a business combination with Curaleaf and raised approximately C$520 million to start raising capital in Canada.


The company made its debut on the Canadian Securities Exchange (CSE) under the ticker symbol “CURA” on Monday. Set at an initial offering price of C$11.45, the stock opened at C$8.70.

At market closure on Monday, the stock declined to C$7.30. The exchange indicated the stock reached a day high of C$10.79.

Curaleaf holds a presence in Arizona, Connecticut, Florida, Maine, Maryland, Massachusetts, Nevada, New Jersey, New York and Oregon.

The company boasted its ownership of 28 cannabis dispensaries, 12 cultivation facilities and 9 processing sites across the US.

Boris Jordan, executive chairman for Curaleaf, told Reuters the company was surprised by the demand and attention it had earned.

“Being one of the larger players in the US, there was a lot of attraction in investing in a company that has a multi-state footprint,” Jordan said.

Following the legalization of adult-use of cannabis in Canada, investors have turned their attention to the US market as the next potential booming area for the sector.

Cannabis investors are able to obtain exposure into the US by investing in multi-state operators with assets in legal cannabis states.

These companies, if public, have turned to the favorable Canadian public sector to raise capital through the CSE.

This exchange, unlike the TMX Group ones, doesn’t restrict cannabis operations in a country where the drug remains illegal on a federal scale.

“We remain committed to growing our business through aggressive organic growth and the strategic deployment of capital into accretive acquisitions that extend our brand into the most attractive US markets,” Joseph Lusardi, CEO of Curaleaf, said in a company statement.

Investor takeaway

The US play has gained steam as a leading play in the cannabis public market as more companies make public debuts to take advantage of the markets’ interest in the sector.

Acreage Holdings announced a reverse takeover to take its stock into the CSE. The company similarly manages assets in legal cannabis states.

Acreage made headlines by adding ex-political figures, such as former Canadian prime minister Brian Mulroney and former Speaker of the United States House of Representatives John Boehner, to its board of directors.

Similarly this market received more attention after iAnthus Capital Holdings (CSE:IAN) made a move to buy the US assets of MPX Bioceuticals (CSE:MPX).

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less